Department of Medicinal Chemistry, University of Washington, Seattle, Washington (D.R.G., M.J.W., W.M.A., A.N.); and Biologics Research, Janssen Research and Development, LLC, Spring House, Pennsylvania (S.H.T., A.Z., M.L.C.).
Department of Medicinal Chemistry, University of Washington, Seattle, Washington (D.R.G., M.J.W., W.M.A., A.N.); and Biologics Research, Janssen Research and Development, LLC, Spring House, Pennsylvania (S.H.T., A.Z., M.L.C.)
Drug Metab Dispos. 2018 Dec;46(12):1900-1907. doi: 10.1124/dmd.118.081893. Epub 2018 Sep 19.
The serum half-life and clearance of therapeutic monoclonal antibodies (mAbs) are critical factors that impact their efficacy and optimal dosing regimen. The pH-dependent binding of an mAb to the neonatal Fc receptor (FcRn) has long been recognized as an important determinant of its pharmacokinetics. However, FcRn affinity alone is not a reliable predictor of mAb half-life, suggesting that other biologic or biophysical mechanisms must be accounted for. mAb thermal stability, which reflects its unfolding and aggregation propensities, may also relate to its pharmacokinetic properties. However, no rigorous statistical regression methods have been used to identify combinations of physical parameters that best predict biologic properties. In this work, a panel of eight mAbs with published human pharmacokinetic data were selected for biophysical analyses of FcRn binding and thermal stability. Biolayer interferometry was used to characterize FcRn/mAb binding at acidic and neutral pH, while differential scanning calorimetry was used to determine thermodynamic unfolding parameters. Individual binding or stability parameters were generally weakly correlated with half-life and clearance values. Least absolute shrinkage and selection operator regression was used to identify the combination of two parameters with the best correlation to half-life and clearance as being the FcRn binding response at pH 7.0 and the change in heat capacity. Leave-one-out subsampling yielded a root mean square difference between observed and predicted half-life of just 2.7 days (16%). Thus, the incorporation of multiple biophysical parameters into a cohesive model may facilitate early-stage prediction of in vivo half-life and clearance based on simple in vitro experiments.
治疗性单克隆抗体(mAbs)的血清半衰期和清除率是影响其疗效和最佳给药方案的关键因素。mAb 与新生儿 Fc 受体(FcRn)的 pH 依赖性结合长期以来一直被认为是其药代动力学的重要决定因素。然而,FcRn 亲和力本身并不是 mAb 半衰期的可靠预测指标,这表明必须考虑其他生物学或生物物理机制。mAb 的热稳定性反映了其展开和聚集倾向,也可能与其药代动力学特性有关。然而,目前还没有使用严格的统计回归方法来确定最佳预测生物学特性的物理参数组合。在这项工作中,选择了一组具有已发表的人体药代动力学数据的 8 种 mAbs 进行 FcRn 结合和热稳定性的生物物理分析。生物层干涉法用于在酸性和中性 pH 下表征 FcRn/mAb 结合,而差示扫描量热法用于确定热力学展开参数。个体结合或稳定性参数通常与半衰期和清除率值弱相关。最小绝对收缩和选择算子回归用于确定与半衰期和清除率相关性最佳的两个参数组合,即 pH 7.0 时的 FcRn 结合反应和热容变化。留一法亚采样得到的观察到和预测半衰期之间的均方根差仅为 2.7 天(16%)。因此,将多个生物物理参数纳入一个有凝聚力的模型中,可能有助于根据简单的体外实验早期预测体内半衰期和清除率。